UNION CITY, Calif., Oct. 21, 2014 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the second fiscal quarter ended September 30, 2014.

Second quarter overview:

• Revenues of $53.9 million, up 18% over last year’s comparable quarter.
• Diluted EPS of $0.24, up 33% over last year’s comparable quarter.

Revenues highlights:

• Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% over last year’s comparable quarter.
• Total medical and veterinary reagent disc revenues of $28.0 million, up 33% over last year’s comparable quarter.
• Total consumables revenues of $38.1 million, up 33% over last year’s comparable quarter.
• Total medical and veterinary reagent disc sales of 2.1 million units, up 30% over last year’s comparable quarter.
• Veterinary market revenues of $45.6 million, up 20% over last year’s comparable quarter.
• North America revenues of $44.5 million, up 19% over last year’s comparable quarter.
• International revenues of $9.4 million, up 11% over last year’s comparable quarter.
• Medical market revenues of $7.6 million, up 6% over last year’s comparable quarter.

Other financial highlights:

• Gross profit of $28.4 million, up 30% over last year’s comparable quarter.
• Income from operations of $8.9 million, up 57% over last year’s comparable quarter.
• Cash, cash equivalents and investments as of September 30, 2014 of $126.3 million, an increase of $5.1 million from March 31, 2014.
• Cash dividend o

  Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015